Showing results (141-150 of 156) with videos related to
Sort By:
Pageof 16
Nature Communications|October 27, 2022
Sea level extremes and compounding marine heatwaves in coastal IndonesiaWeiqing Han, Lei Zhang, Gerald A Meehl, et al.Microbiology (Reading, England)|June 30, 2007
A group of Escherichia coli and Salmonella enterica O antigens sharing a common backbone structureWei Wang, Andrei V Perepelov, Lu Feng, et al.Translational Andrology and Urology|July 18, 2020
A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urineCheng Zhao, Yi Pan, Yinhuai Wang, et al.BMC Medicine|March 4, 2022
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trialXiaojian Qin, Dongmei Ji, Weijie Gu, et al.Nature Chemical Biology|April 27, 2010
In vitro bacterial polysaccharide biosynthesis: defining the functions of Wzy and WzzRobert Woodward, Wen Yi, Lei Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaXinan Sheng, Xieqiao Yan, Lin Wang, et al.European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical TrialsXinan Sheng, Lin Wang, Zhisong He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialFred Saad, Egils Vjaters, Neal Shore, et al.Pageof 16